The Week Ahead: Hom...
Health Care: Drugs
Threshold Pharmaceuticals Inc. (THLD: NASDAQ)
$5.48 -0.09 | -1.62%
05/20/13 - 04:00 PM ET
Company Balance Sheet
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 11.03M | 5.88M | 8.69M | 8.93M |
| Receivables | 15.64M | 0.00 | 0.00 | 0.00 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Assets | 87.65M | 20.54M | 15.64M | 47.66M |
| Property, Plant & Equipment, Gross | 2.55M | 2.29M | 5.04M | 4.94M |
| Accumulated Depreciation & Depletion | 1.74M | 1.75M | 4.77M | 4.43M |
| Property, Plant & Equipment, Net | 812.00K | 543.00K | 271.00K | 505.00K |
| Intangibles | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Assets | 1.06M | 1.35M | 290.00K | 523.00K |
| Total Non-Current Assets | 1.87M | 1.89M | 561.00K | 1.03M |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 89.52M | 22.44M | 16.20M | 48.68M |
| Accounts Payable | 908.00K | 2.39M | 252.00K | 284.00K |
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Liabilities | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Liabilities | 17.45M | 8.59M | 3.51M | 12.87M |
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Income Taxes | 268.00K | 153.00K | 248.00K | 0.00 |
| Other Non-Current Liabilities | 85.66M | 9.21M | 7.50M | 13.15M |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 85.92M | 9.36M | 7.75M | 13.15M |
| Total Liabilities | 103.37M | 17.95M | 11.26M | 26.03M |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | -13.85M | 4.48M | 4.94M | 22.66M |
| Common Par | 56.00K | 49.00K | 34.00K | 33.00K |
| Additional Paid In Capital | 309.34M | 256.56M | 231.38M | 230.44M |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -323.26M | -252.13M | -226.48M | -207.79M |
| Treasury Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Equity Adjustments | 11.00K | -1.00K | 1.00K | -24.00K |
| Total Capitalization | -13.85M | 4.48M | 4.94M | 22.66M |
| Total Equity | -13.85M | 4.48M | 4.94M | 22.66M |
| Total Liabilities & Stock Equity | 89.52M | 22.44M | 16.20M | 48.68M |
| Total Common Shares Outstanding | 56.43M | 49.13M | 33.70M | 33.56M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic Weighted Shares Outstanding | 54.22M | 45.90M | 33.65M | 19.59M |
| Diluted Weighted Shares Outstanding | 54.22M | 45.90M | 33.65M | 19.59M |
| Number of Employees | 48 | 31 | 36 | 31 |
| Number of Part-Time Employees | 0 | 0 | 0 | 0 |
Portfolios with THLD
- Portfolio NameUser Type
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- UserBasement money
- UserStock Interests, Ideas & Re...
- UserMy Watch
- UserGopher Gold
- UserBlue Horseshoe loves Andeco...
- UserJARBAS ROCHA
Latest THLD Headlines from TheStreet
- 5 Stocks Poised for Breakouts 03.01.13 | 02:03 pm
- 4 Biotech Stocks Under $10 Moving Higher 02.20.13 | 09:02 pm
- 3 Biotech Stocks Under $10 Moving Higher 02.12.13 | 02:02 pm
- Stocks Continue to Climb as Companies Exceed Expectations 01.25.13 | 04:01 pm
- Biotech Stock Mailbag: Keryx, Sangamo, Threshold and Amarin 01.25.13 | 07:01 am
- Celgene's Abraxane: Two Month Survival Boost In Pancreatic Cancer Trial 01.22.13 | 06:01 pm
- 4 Biotech Stocks Spiking on Unusual Volume 01.08.13 | 02:01 pm
- 10 Best-Performing Biopharma Stocks of 2012 and Their 2013 Outlook 11.27.12 | 06:11 am
- Nate Sadeghi's 2012 Biotech Stock Report Card 11.26.12 | 07:11 am
- Celgene: Abraxane Boosts Pancreatic Cancer Survival 11.12.12 | 12:11 am
Press Releases for THLD
- SHAREHOLDER ALERT: The Law Firm Of Levi & Korsinsky, LLP Launches An Investigation Into Possible Breaches Of Fiduciary Duty By The Board Of Directors Of Threshold Pharmaceuticals Inc. - PR Newswire 04.03.13 | 05:04 pm
- Threshold Pharmaceuticals Reports Second Quarter 2011 Financial And Operational Results - Business Wire 08.04.11 | 04:08 pm
- Threshold Pharmaceuticals Announces Initiation Of Clinical Trial Evaluating TH-302 In Combination With Bevacizumab At University Of Texas At San Antonio - Business Wire 07.25.11 | 09:07 am
- Threshold Pharmaceuticals Announces National Comprehensive Cancer Network (NCCN) Grant For Phase 1 Trial Of TH-302 In Combination With Pazopanib - Business Wire 07.06.11 | 08:07 am
- Threshold Pharmaceuticals Initiates Clinical Trial Evaluating TH-302 In Combination With Sunitinib - Business Wire 06.29.11 | 06:06 am
- Threshold Pharmaceuticals To Present At OneMedForum Conference - Business Wire 06.22.11 | 06:06 am
- Threshold Pharmaceuticals Announces Completion Of Patient Recruitment For Phase 2 TH-302 Pancreatic Cancer Study - Business Wire 06.21.11 | 04:06 pm
Partner Headlines for THLD
- 3 Biotechs And The Feuerstein-Ratain Rule - Seeking Alpha 04.09.13 | 09:04 am
- Threshold Pharmaceuticals - A Derivative Trade On Ziopharm's Upcoming Data - Seeking Alpha 03.22.13 | 09:03 am
- UPDATE: Maxim Group Initiates Threshold Pharmaceuticals at Buy on Doxorubicin Potential - Benzinga 09.20.12 | 01:09 pm
- Today's Market News To Trade On: 5 Stocks Moving On News - Seeking Alpha 09.18.12 | 09:09 am
- Morning Market Losers - Benzinga 09.17.12 | 09:09 am
- Buy Zalicus For A 120% Upside - Seeking Alpha 09.05.12 | 09:09 am
- Worthington INITIATED Buy and 3 Analyst-Initiated Stocks To Note - Wall St. Cheat Sheet 07.10.12 | 04:07 am
- Best Performing Stocks At 2012's Midpoint - Seeking Alpha 06.29.12 | 07:06 pm
- Healthcare Biz Recap: Express Scripts New Driver, Elan Pops - Wall St. Cheat Sheet 05.27.12 | 12:05 pm
- Analyst Insights: Fresh Market, Air Methods, Threshold Pharmaceuticals, Williams Companies, Synaptics May 25th - Wall St. Cheat Sheet 05.25.12 | 10:05 am
